What is the history of IgA nephropathy?

IgA nephropathy, also known as Berger’s disease, was first described by French nephrologist Jean Berger and his colleague Nicole Hinglais in 1968 after they utilized immunofluorescence microscopy to identify characteristic deposits in kidney biopsies. Since its initial identification, our understanding of IgA nephropathy has shifted from a perceived benign condition to a complex autoimmune disorder that is now recognized as the most common form of primary glomerulonephritis worldwide.

When and how was IgA nephropathy first identified?

Before 1968, the underlying cause of many cases of recurrent hematuria (blood in the urine) remained a mystery, often categorized under vague clinical descriptions. The history of IgA nephropathy changed forever when Jean Berger and Nicole Hinglais published their landmark findings in Journal d'Urologie et de Néphrologie. By employing immunofluorescence techniques, they observed granular deposits of immunoglobulin A (IgA) in the mesangium of the kidney's filtering units (glomeruli). This discovery provided a clear histological definition for what we now recognize as IgA nephropathy.

How has the understanding of IgA nephropathy evolved?

In the early decades following its discovery, IgA nephropathy was frequently mischaracterized as a benign, non-progressive disease. However, longitudinal studies conducted throughout the 1970s and 1980s revealed that a significant portion of patients—roughly 20% to 40%—eventually progress to end-stage renal disease (ESRD) over 20 years. This correction in clinical perception led to more aggressive monitoring and earlier interventions. Modern research has moved beyond the kidney itself, focusing on the "multi-hit hypothesis," which suggests that the disease is driven by the production of galactose-deficient IgA1, which then triggers an autoimmune response.

What are the major milestones in the management of the condition?

The treatment landscape for IgA nephropathy has evolved from non-specific supportive care to targeted immunomodulatory therapies. Key milestones include:

• 1990s: The widespread adoption of ACE inhibitors and ARBs to manage proteinuria and slow the progression of kidney damage.


• 2010s: The development of the Oxford Classification (MEST-C score), which allowed pathologists to standardize the reporting of kidney biopsy findings to better predict patient outcomes.


• 2021-Present: The emergence of targeted therapies, such as budesonide (a targeted-release corticosteroid) and sparsentan, which aim to reduce the specific immune activity driving IgA nephropathy.

How has technology and patient advocacy changed the landscape?

The integration of genome-wide association studies (GWAS) has identified specific genetic loci associated with IgA nephropathy, proving that the condition has a strong hereditary predisposition. This genetic insight has allowed for better risk stratification. Simultaneously, patient advocacy has transformed from isolated experiences to global networks. Today, more than 347 people with IgA nephropathy have joined the DiseaseMaps.org community, sharing their experiences and accelerating the collective understanding of how this disease impacts daily life, which in turn informs clinical research and emotional support strategies.

Next steps

• Consult with a nephrologist who specializes in glomerulonephritis to discuss the most recent clinical guidelines.


• Join the IgA nephropathy community on DiseaseMaps.org to connect with others who share your journey.


• Ask your medical team about the Oxford Classification (MEST-C score) from your biopsy to better understand your specific risk profile.


• Stay updated on active clinical trials via the NIH ClinicalTrials.gov database.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): IgA Nephropathy.


• Orphanet: Berger's disease (IgA nephropathy).


• OMIM (Online Mendelian Inheritance in Man): IgA Nephropathy 1 (IGAN1).


• Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines.